|
Market Closed -
London S.E.
11:35:06 2026-11-03 EST
|
5-day change | 1st Jan Change | ||
| 1,827.50 GBX | +0.16% |
|
-4.99% | +0.16% |
| 07:21am | GSK plc : Receives a Sell rating from JP Morgan | ZD |
| 07:11am | GSK plc : Berenberg remains its Buy rating | ZD |
| Market Cap | 73.14B 98.14B 87.68B 80.54B 137B 9,297B 141B 961B 387B 4,907B 368B 360B 15,552B | P/E 2026 * |
14.6x | P/E 2027 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise Value | 94.82B 127B 114B 104B 178B 12,051B 183B 1,246B 501B 6,361B 478B 467B 20,161B | EV / Sales 2026 * |
2.8x | EV / Sales 2027 * | 2.61x |
| Free-Float |
94.95% | Yield 2026 * |
3.81% | Yield 2027 * | 4.1% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| GSK | Delayed | |
CBOE
| GSK | Real-time | |
|
Xetra
| GS71 | Delayed | |
|
OTC Markets
| GLAXF | Delayed | |
|
Tradegate
| GS71 | Real-time | |
|
Boerse Muenchen
| GS71 | Real-time | |
|
Mexican S.E.
| GSK1 N | End-of-day quote | |
|
Deutsche Boerse AG
| GS71 | Delayed | |
|
Börse Stuttgart
| GS71 | Delayed | |
|
Bulgaria S.E.
| GS71 | End-of-day quote |
Last Transcript: GSK plc
| 1 day | +0.19% | ||
| 1 week | -4.99% | ||
| Current month | -1.48% | ||
| 1 month | +3.89% | ||
| 3 months | -4.29% | ||
| 6 months | -1.59% | ||
| Current year | +0.16% |
| 1 week | 1,783.5 |  | 1,879.5 |
| 1 month | 1,735.5 | | 2,158 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,690 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 9/18/26 | Buy | Director | 768 | 0.0000% | ||
| 9/18/26 | Buy | Director | 1,734 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | -4.99% | +4.01% | +30.95% | 98.15B | |
| +0.56% | +10.89% | +58.56% | +150.35% | 1,257B | |
| -1.19% | -0.56% | +43.47% | +76.58% | 651B | |
| -0.61% | +0.53% | +35.84% | +103.59% | 510B | |
| -1.56% | -2.01% | +50.67% | +64.81% | 388B | |
| -2.56% | +2.06% | +75.47% | +40.01% | 366B | |
| -0.02% | +2.11% | +32.16% | +57.79% | 303B | |
| -0.72% | +7.32% | +11.29% | +33.98% | 288B | |
| -0.68% | +3.41% | +56.34% | +71.66% | 252B | |
| -0.56% | +6.79% | +39.19% | +108.21% | 211B | |
| Average | -0.67% | +3.66% | +40.70% | +73.79% | 432.48B | |
| Weighted average by Cap. | -0.52% | +5.07% | +47.01% | +93.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.84B 45.41B 40.57B 37.26B 63.55B 4,301B 65.15B 445B 179B 2,270B 170B 167B 7,195B | 35.28B 47.34B 42.29B 38.85B 66.26B 4,484B 67.92B 464B 187B 2,367B 178B 174B 7,502B |
| Net income | 5.01B 6.72B 6.01B 5.52B 9.41B 637B 9.65B 65.85B 26.49B 336B 25.23B 24.69B 1,065B | 6.1B 8.18B 7.31B 6.71B 11.45B 775B 11.74B 80.12B 32.23B 409B 30.7B 30.04B 1,296B |
| Net Debt | 21.67B 29.08B 25.98B 23.86B 40.7B 2,755B 41.73B 285B 115B 1,454B 109B 107B 4,608B | 18.97B 25.46B 22.74B 20.89B 35.63B 2,412B 36.53B 249B 100B 1,273B 95.56B 93.51B 4,034B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-03 | GBX 1,827.50 | +0.16% | 3,272,943 |
| 26-11-02 | GBX 1,824.50 | -1.64% | 5,439,808 |
| 26-10-30 | GBX 1,855.00 | +2.26% | 13,550,560 |
| 26-10-29 | GBX 1,814.00 | -0.96% | 9,352,307 |
| 26-10-28 | GBX 1,831.50 | -4.78% | 16,830,181 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
